Register for New Oral Anticoagulants

GWT-TUD GmbH5,000 enrolled

Overview

Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register. Within this register a characterization of patients (with regard to demography and indication) and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Anticoagulation Treatment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * indication for treatment with long term anticoagulation * initial adjustment or change to nex oral anticoagulant within routine treatment * indication for treatment with long term anticoagulation within the register: * permanent anticoagulation in arterial fibrillation * intended anticoagulation in acute venous thromboembolism for min. 3 months * other anticoagulation for min. 3 months within the approved indication Exclusion Criteria: * missing Informed Consent Form * missing phone number for telephone follow up * contraindication for therapy with new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) according to Summary of Product Characteristics

Locations (1)

Universitätsklinikum Dresden on behalf of GWT-TUD GmbH

Dresden, Germany

RECRUITING

Central Contacts

Jan Beyer-Westendorf, MD

CONTACT

+49 351 458 jan.beyer@uniklinikum-dresden.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.